H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, is pleased to announce the appointment of Tarek Sahmoud, MD, PhD, as Chief Medical Officer.
Cambridge, Mass., June 1, 2016 — H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, is pleased to announce the appointment of Tarek Sahmoud, MD, PhD, as Chief Medical Officer.
Dr. Sahmoud has more than 20 years of experience in oncology drug development and medical affairs. During his career, he has led global drug development programs for several novel oncology drugs in multiple indications, including adjuvant breast cancer (Arimidex), hormone receptor positive breast cancer (Afinitor) and Tuberous Sclerosis (Afinitor), resulting in successful global registrations. His experience also includes the development and leading of global and US medical affairs teams, multi-disciplinary teams of physicians and clinical scientists, as well as serving as on the protocol review committee of a number of companies.
“Tarek’s appointment comes at a critical juncture in H3’s growth, as the company is entering the clinic with two oncology drug candidates that he will lead through the development cycle,” said Markus Warmuth, MD, President and CEO of H3 Biomedicine. “I am confident that his proven leadership skills and established oncology knowledge will be a key ingredient in our clinical growth and future success.”
Prior to joining H3 Biomedicine, Dr. Sahmoud most recently served as Vice President, Oncology Clinical Development and Medical Affairs for the United States business at Boehringer Ingelheim. Before his tenure at Boehringer Ingelheim, Dr. Sahmound held positions of increasing global responsibilities at AstraZeneca, Bristol-Meyers Squib, Novartis, and Celgene.
“Leading this team of committed scientists and drug developers at such an important time in H3’s evolution presents incredible opportunity for me. I am eager to lead the company’s growing development programs,” Dr. Sahmoud said. “This position provides an excellent opportunity to develop precision treatments for cancer patients with highly unmet medical need. Together with our established leadership team, I look forward to accelerating the development of our pipeline and bringing much-needed cancer therapeutics to patients. Cancer is the enemy and time is of the essence.”
Dr. Sahmoud received his medical degree from Cairo University Medical School, Egypt and a Ph.D. from University Bordeaux II, France.
About H3 Biomedicine Inc.
H3 Biomedicine is a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of precision oncology treatments. Leveraging collaboration with Eisai, Co, Ltd., who through this partnership provides essential research funding and access to the capabilities and resources of this global pharmaceutical company, H3 Biomedicine combines long-term vision with operational independence. Using modern synthetic chemistry, chemical biology, and human genetics, H3 Biomedicine seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. For more information, please visit h3biomedicine.com.